Characterization of a TGFbeta-responsive human trophoblast-derived cell line.
The placenta is formed by developing trophoblast cells to facilitate fluid, gas and nutrient exchange with the mother. Inappropriate trophoblast responsiveness can lead to life threatening complications during pregnancy including intrauterine growth retardation, pre-eclampsia, spontaneous abortion and malignancy that could lead to fetal loss. Transforming growth factor beta (TGFbeta) is a multifunctional cytokine required for embryonic development and is an important regulator of human trophoblast function. Although TGFbeta is critical for placental and embryonic development, there are currently no established TGFbeta-responsive human trophoblast-derived cell lines available to study the mechanisms by which TGFbeta regulates trophoblast function. Our studies have examined the transformed human trophoblast-derived cell line, ED27, to determine if it is responsive to TGFbeta. Our data indicate that TGFbeta dose responsively and reversibly inhibits cell growth in ED27 cells and induces classic TGFbeta response genes, fibronectin and plasminogen activator inhibitor 1 (PAI-1). TGFbeta also induces an inhibitor of trophoblast invasion, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in ED27 cells. Our studies have identified a human trophoblast-derived cell line that parallels isolated primary human trophoblasts in their responses to TGFbeta. This cell line may provide us with the opportunity to determine TGFbeta-mediated responses on human trophoblast functions not previously possible.
Smith
A N
AN
Department of Physiology and Cell Biophysics, Wright State University School of Medicine, Dayton, Ohio 45435, USA.
Carter
Q L
QL
Kniss
D A
DA
Brown
T L
TL
D017209:Apoptosis; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D002470:Cell Survival; D003600:Cytosol / Q000737:chemistry; D004247:DNA / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D020287:In Situ Nick-End Labeling; D020782:Matrix Metalloproteinases / Q000502:physiology; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis; D011247:Pregnancy; D020218:Response Elements; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000096:biosynthesis; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D014327:Trophoblasts / Q000187:drug effects / Q000502:physiology*
D006131:Growth Inhibitors; D017395:Plasminogen Activator Inhibitor 1; D019715:Tissue Inhibitor of Metalloproteinase-1; D016212:Transforming Growth Factor beta; D004247:DNA; D020782:Matrix Metalloproteinases